New insights into heart’s healing capacity – Baylor College of Medicine News

A group of researchers at Baylor College of Medicine, the Texas Heart Institute and the University of Texas Health Science Center at Houston reveals today in the journal Genes & Development new insights into the recently discovered healing capacity of the heart involving the Hippo cellular pathway. The group previously reported that inactivating the Hippo pathway in the adult murine heart promoted cardiac muscle regeneration after injury, opening the possibility of developing promising heart failure therapies.

In this study, the researchers discovered that inactivating the Hippo pathway in cardiac fibroblasts, non-muscle heart cells intertwined with cardiac muscle cells, promoted cardiac fibrosis and adversely effected cardiac function. These results highlight the need for targeting the Hippo pathway specifically in cardiac muscle cells, and not in cardiac fibroblasts, for safe and effective heart failure therapy.

Heart failure remains the leading cause of mortality in the U.S., and one of the interests of my lab is to develop ways to heal heart muscle by studying cellular pathways involved in heart development and regeneration, said corresponding author Dr. James F. Martin, professor and Vivian L. Smith Chair in Regenerative Medicine atBaylor and director of theCardiomyocyte Renewal Lab at the Texas Heart Institute.

During a heart attack, blood stops flowing into the heart; without oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with a scar, made from cells called fibroblasts. If there is too much scarring, the heart progressively weakens; a large proportion of people who had a severe heart attack will develop heat failure and scarring in the heart.

In previous studies, Martin and his colleagues discovered that inactivating the Hippo signaling pathway in adult murine hearts triggered cardiac muscle cell regeneration after heart attack. These findings raised hope for the development of promising heart failure therapies involving the Hippo pathway.

In the current study, Martin and his colleagues further investigated the Hippo pathway in the adult murine heart, this time focusing on its role in cardiac fibroblasts, non-muscle cells that are closely associated with cardiac muscle cells. The researchers conducted a number of basic studies, including single cell sequencing experiments that provided a high level of resolution to their analyses.

We inactivated the Hippo pathway in resting adult hearts that did not have any injury and observed that the fibroblasts became activated; they proliferated and developed into myofibroblasts, a major cell type that appears in heart tissues after an injury, Martin said.

Mouse hearts with a deficient Hippo pathway in cardiac fibroblasts spontaneously developed cardiac fibrosis, even without injury, which resulted in severe heart dysfunction, said co-first author Dr. Yang Xiao, who was a postdoctoral fellow in the Martin lab during this project. This and other evidence indicated that the Hippo pathway is required to restrain cardiac fibrosis; Hippo is important for maintaining the fibroblasts in their resting state.

In addition, the researchers found that inactivating the Hippo pathway also triggered a molecular cascade resulting in an inflammatory response that was mediated by Yap, a molecule that regulates a number of molecular pathways.

We know that Hippo and Yap work together. Hippo acts like a brake for Yap, so when we took away Hippo, Yap remained active and regulated the expression of important signaling molecules that talk to macrophages and other immune cells luring them into the heart, Martin said.

The researchers believe they have identified important insights into heart function. Their findings inform about the genetic pathways that are important for maintaining the fibroblasts in their resting state.

Other contributors to this work include co-first author Matthew C. Hill, Lele Li, Vaibhav Deshmukh, Thomas J. Martin and Jun Wang. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, the Texas Heart Institute and the University of Texas Health Science Center at Houston.

This study was supported by grants from the National Institutes of Health (DE023177, HL127717, HL130804, HL118761; F31HL136065; K01DE026561); American Heart Association (14SDG19840000), Vivian L. Smith Foundation, State of Texas funding, Fondation LeDucq Transatlantic Networks of Excellence in Cardiovascular Research (14CVD01) Defining the genomic topology of atrial fibrillation. Further support was provided by Intellectual and Developmental Disabilities Research Center grant number 1U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Mouse Phenotyping Core at Baylor College of Medicine (U54 HG006348).

Read the original post:
New insights into heart's healing capacity - Baylor College of Medicine News

Meet Noveel Pandya: Indian multi-millionaire whose stem cell venture project is the talk of town – Gulf News

At 34, Noveel Pandya is an aspiring billionaire who has made it big right here in the UAE. Image Credit: Atiq-ur-Rehman / Gulf News

Dubai: At 34, Noveel Pandya is a billionaire who has made it big right here in the UAE. While it would bealright to say he is more blessed than others his father, Narendra Pandya, ran an established business in the UAE before Noveel started Noveel is attempting to makea mark withhis own venture,Bioscience Clinic Middle East.

Senior Pandya runs a successful business House of Chemicals (HOC) - as a distributor of specialty and commodity chemicals for key suppliers especially in businesses such as oil drilling, refineries, gas plants, lubricant plants, water treatment for desalination plants and sewage treatment.

Pandya,Noveels father,also started another company BDH with an expertise in supply, installation, commissioning and maintenance of all laboratory equipment and furniture.

We are pretty much the turnkey laboratory projects expert, said Noveel, in an interview with Gulf News at his house in Emirates Hills.

But Noveels babyBioscience Clinic Middle East a center offering regenerative medicine and personalised autologous cell therapies brings him much pride and cheer. Premium services of the company include cryopreservation and expansion of cells used for anti-aging treatments, aesthetic and plastic surgery, wound care and for dermatological imperfections.

Starting from the bottom up

With a family-run business, it was perhaps a given for Noveel to become a businessman himself and run his fathers mantle.

But this was not achievedbefore he had to work his way up to the top.

In fact I started from bottom low. There was no way my father was going to have me take over peoples jobs in the company who had put in years of hard work. So there was a huge process of learning one that taught me humility and gratitude for the people who are part of our team, he said.

Noveels father came to work in the UAE in the early 70s. He said, From the stories I hear from him - there were many challenges and struggles he faced. In fact, lots of people who came with him to work in the UAE returned home.

It wasn't handed on a platter

Before jumping to the conclusion that he had it all easy,Noveel had to prove his capabilities just like any employee of the firm and had to work his way up the ladder.

There was no way my father was going to let me work above all those people who had put in so many years of service. From 2007 until 2011 it was all about learning and observation.

Take this: From the time Noveel completed his MBA in London in 2011 to join the family, he has helped the family business grow by a 100 per cent year on year.

Noveel said, BDH for example was making Dh35 million in 2007, but today, it is making over Dh140 million.

As for his own venture, there is massive potential for Bioscience Clinic Middle East as the stem cell venture business for the MENA region is tipped to be around two million dollars.

According to a report published in April 2019, the global stem cell market size is expected to reach $15.63 billion by 2025.

Today, we have little competition in the MENA region, so as you can see, there is a massive potential to grow.

Reverse-aging with stem cell therapy

Noveel said typically a client would reach out to a clinic to undergo a full scan and evaluation. A consultation with specialised doctors follows. Once the evaluation is done and the patient passes the test to become a candidate for the stem cell venture project, the doctor executes a plan to extract fat from the persons body.

This fat stores stem cells and we extract it from the fat. We have advanced technology in place to do the job for this. The stem cells derived are stored in vials and frozen, he explained.

The stem cells are multiplied to a couple of hundred million or sometimes a billion in order to produce the required volume.

Noveel said: When the stem cells are frozen they stop the ageing process of the cells. This means it effectively helps reverse-age a person. If someone at the age of 30 comes to us and asks us to freeze their cells. We do it. The person can always come back ten or 15 years later to rejuvenate their skin, hair or any part of their body. Just imagine at 45 or 50, this person wants to rejuvenate their skin. What we will do is inject their cells which were frozen when they were 30. When these cells are injected, they will leave the person with a skin looking as young as 30.

Stem cell therapy is said to be the most natural way to rejuvenate your skin, body and cells. The concept is called autologous which means it is your own cells which go into your body - not that of siblings or parents. Basically it is your own cells which are injected to the body and it is the most natural way to rejuvenate your body and skin.

How long does it take for the body to rejuvenate?

It depends on the body type, the persons lifestyle, food habits and more. This can take from a couple of weeks to a whole month. Remember, this is not an overnight fix. In fact treatments that come with overnight fixes can be very dangerous. Anything that has a drastic effect on your body is not good at all, explained Noveel.

We have seen fine lines or wrinkles disappearing in seven to 15 days after the cells were injected. The effect of the cell injected can last up to a year or over a year. But it all depends on the body type. Remember, your body can never reject your own cells it always accepts its cells.

Our clients are people from the age 18 and above. People who use alternative treatments come to us. I had a 63-year-old man come in from India saying they wanted their stem cells extracted.

Screening process

When a person comes there is a screening process that goes in. Upon successfully passing the screening process, other factors expel candidates like those who are typically heavy smokers or people with certain existing medical conditions. If a client has a virus present in the body, that would drastically effect the quality of cells. If the quality of cells we get right in the beginning is poor the effect will not be desirable for them. Similarly, if the person is diagnosed with some STDs, certain terminal illness, we do not recommend them to store their cells.

Package cost

An initial package offered by Bioscience Clinic Middle East is close to Dh15,000 which includes a consultation, cell extraction, one year storage of stem cells and application. The application can be used anytime. One is not forced to use it immediately.

We are the only business in the region offering such services, Noveel claimed.

Business investment

Noveel said he invested 5 million euros in Bioscience Clinic Middle East.

This money went in for the facilitation of the lab, the treatment, and consultation, hiring skilled professionals and setting up class clean rooms for storing stem cells. Remember we are talking about a niche industry and a very niche product. The investment is for this.

Challenges as a millennial

There is a definite need to make an effort to be heard. Sometimes we are not taken seriously and that is the only challenge I see for myself today. But never give up. Keep dreaming and have the zest to grow. Patience is a virtue that we millennials need to build. Success does not come overnight. For example, my break-even did not happen for long. But I kept at my dreams and went after my goals. This is critical, Noveel said

Read this article:
Meet Noveel Pandya: Indian multi-millionaire whose stem cell venture project is the talk of town - Gulf News

BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa – BioSpace

CAMBRIDGE, Mass., Sept. 25, 2019 /PRNewswire/ --BlueRock Therapeutics, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock and Vice Chairman of the Alliance for Regenerative Medicine (ARM), will present at the Cell & Gene Meeting on the Mesa, to be held Oct. 2-4 in Carlsbad, Calif.

The following are specific details regarding BlueRock's participation at the conference:Event: BlueRock Therapeutics Company PresentationDate: Wednesday, Oct. 2Time: 11:45 a.m. - 12:00 p.m. PDTLocation: Cognate Bioservices Ballroom,Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011

Event: Panel: Cell and Gene Therapy for Neurological Product IndicationsDate: Wednesday, Oct. 2Time: 4:00 - 5:00 p.m. PDTLocation: BlueRock Therapeutics Ballroom, Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011

A live video webcast of all company presentations and workshops will be available at: http://www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 80 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

About BlueRock Therapeutics BlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics'CELL+GENE platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics' cell differentiation technology recapitulates the cell's developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock's culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit http://www.bluerocktx.com.

Company Contact:Candice Ellis, 978-879-7273Associate Director, Investor Relations and Corporate Communicationscellis@bluerocktx.com

Media Contacts: David Schull or Maggie BellerRusso Partners, LLC(646) 942-5631Maggie.beller@russopartnersllc.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/bluerock-therapeutics-to-present-at-2019-cell--gene-meeting-on-the-mesa-300925107.html

SOURCE BlueRock Therapeutics

See the article here:
BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa - BioSpace

Novel CAR T-cell therapy for leukaemia and lymphoma targets BAFF-R – Drug Target Review

Scientists in the US have developed a promising new CAR T-cell therapy that targets the BAFF-R protein, which has demonstrated superior cancer destruction to existing FDA-approved CAR-T therapies.

The first CAR T-cell therapy targeting the B cell-activating factor receptor on cancerous cells, eradicated CD19-targeted therapy-resistant human leukaemia and lymphoma cells in animal models, according to research by theCity of Hope.

The new therapy will be used in a clinical trial next year for patients who relapsed after CD19 immunotherapy treatments and may also be potentially used as a first-line of CAR T-cell therapy treatment.

An estimated 20 to 30 percent of leukaemia and lymphoma patients who achieve remission after receiving CD19 CAR-T therapy will relapse after a few years. The effectiveness of the CAR-T cells that target the CD19 protein on cancerous B cells begins to wane and the cancer returns.This new therapy offers a possible solution for such patients.

One major obstacle to current CAR-T therapy is that in up to a third of these patients, the tumour is actually smart and comes back because it has learned how to no longer express the target thats recognised by the original immunotherapy, saidLarry Kwak, MD, PhD, vice president and deputy director of City of Hopes comprehensive cancer center and the studys principal author, who leads the research with Hong Qin, PhD, a research professor in City of Hopes Department of Hematology & Hematopoietic Cell Transplantation.

To combat that, City of Hope research has found a new, and potentially more effective, target for CAR T-cell therapy against B cell leukaemias and lymphomas. We plan to open a clinical trial next year using the BAFF-R CAR T-cell therapy.

This new treatment could change the face of leukaemia and lymphoma treatment in the US and worldwide, added Kwak, the Dr Michael Friedman Professor in Translational Medicine.

CAR T-cell therapy involves taking a patients T cells from the bloodstream. The immune cells are then genetically engineered in a laboratory to recognise and attack a specific cancer-associated protein, such as BAFF-R, before being reintroduced into the patients bloodstream, whereupon they begin destroying tumour cells.

For this study, animal models with CD19 therapy-resistant human-tumours (including Burkitt, mantel cell, and other non-Hodgkins lymphoma subtypes and acute lymphoblastic leukaemia) received BAFF-R CAR-T therapy. Remarkable tumour regression and prolonged survival were observed after treatment with these CAR-T cells. In animal models with human Burkitt lymphoma, BAFF-R CAR-T therapy achieved a cure (complete tumour regression with 100 percent long-term survival) after a single treatment.

Tumour samples from patients who relapsed after receiving CD19-targeted immunotherapy (blinatumomab) were also investigated. The study demonstrated that BAFF-R CAR-T cells were consistently active against these tumours, whereas CD19 CAR-T cells had greatly diminished responses to each patients relapse tumour compared to the pre-therapy samples.

We did a head-to-head comparison of two new therapies and our data showed that our BAFF-R CAR-T therapy actually did a better job than FDA-approved CD19 CAR-T therapies, Qinsaid. If these results continue, we will pursue BAFF-R CAR-T therapy as a kind of frontline CAR-T therapy treatment for lymphoma and leukaemia patients.

City of Hope plans to open a clinical trial next year using the BAFF-R CAR T-cell therapy for B cell leukaemia and lymphoma patients who have relapsed after receiving CD19 CAR T-cell therapies or blinatumomab.

This research was published inScience Translational Medicine.

View original post here:
Novel CAR T-cell therapy for leukaemia and lymphoma targets BAFF-R - Drug Target Review

PolarityTE Selected to Present at 2019 Cell & Gene Meeting on the Mesa – Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that Nikolai Sopko, MD, PhD, Chief Scientific Officer of PolarityTE, was selected to present at the annual Cell & Gene Meeting on the Mesa, which will be held from October 2-4, 2019 in Carlsbad, California. Dr. Sopko will discuss the Companys R&D pipeline and highlight the progress made thus far with the Companys first clinically available product, SkinTE, an autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for use in wounds, traumas, and burns.

PolarityTE is scheduled to present on October 3rd from 9:45-10am PST in the Cognate Bioservices Ballroom, Park Hyatt Aviara Resort.

A live video webcast of all company presentations will be available at: http://www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event. Please visit http://www.meetingonthemesa.com for full information on the conference, including registration.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 80 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

About PolarityTE

PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at http://www.PolarityTE.com Welcome to the Shift.

About SkinTE

SkinTE is a human cellular and tissue-based product derived from a patient's own skin intended for the repair, reconstruction, and replacement of skin tissue. SkinTE has been proven to regrow skin over exposed bone, muscle, joint and tendon and has been used to treat a variety of skin defects, including burns, wounds, traumatic injuries, surgical reconstruction, scars, and failed skin grafts or conventional treatments for wounds and burns.

SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE is marketed as an HCT/P regulated by the FDA solely under Section 361 of the Public Health Service Act and 21 CFR 1271.

Forward Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, WELCOME TO THE SHIFT, and SKINTE are trademarks or registered trademarks of PolarityTE, Inc.

Continued here:
PolarityTE Selected to Present at 2019 Cell & Gene Meeting on the Mesa - Business Wire

Natera Sees Foundation Medicine Deal as "Additive" to Other Cancer Monitoring Opportunities – GenomeWeb

NEW YORK Natera's recent deal with Foundation Medicine to develop personalized cancer monitoring assays will allow it to piggyback on the Roche subsidiary's dominant market share in tumor genomic profiling to establish its Signatera test for use in advanced cancer patients, while continuing to pursue other opportunities for the test on its own.

Foundation Medicine, on the other hand, is banking on Natera's technology and expertise in circulating tumor DNA analysis to bring monitoring assays to patients more quickly than it could on its own.

GenomeWeb Premium gives you: Full site access Interest-based email alerts Access to archives Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?Login Now.

*Before your trial expires, well put together a custom quote with your long-term premium options.

Read this article:
Natera Sees Foundation Medicine Deal as "Additive" to Other Cancer Monitoring Opportunities - GenomeWeb

Don’t Be Shy About Asking to Remain in the Hospital – Sickle Cell Anemia News

One of the best feelings in the world is cutting a hospital bracelet.

Cutting a hospital bracelet can symbolize a fresh start. Youve been discharged from the hospital. You are feeling like the best version of yourself happy, relaxed, optimistic, and ready to prove that sickle cell cant keep you down.

However, sometimes I feel like hospital bracelets are cut prematurely.

I was admitted to the hospital Sept. 13 because of a vaso-occlusive crisis. I had pain in my arms, my back, and my legs. I was taking oral morphine, dihydrocodeine, and acetaminophen every four hours. I wouldve been arrested if I had been caught driving in that state.

It was frustrating, because every time the medications wore off, the pain was just as intense as it was before I was admitted. The pain wasnt getting better. In fact, the pain was getting worse, which meant the medicine just kept coming.

Days passed. It got to the point where every doctor, nurse, and consultant suggested I leave the hospital, as I could use the same painkillers at home. I declined each time.

I hate going to the hospital so much that I treat it as a last resort. You know its serious if I take myself to the emergency room. I need help that I cant sufficiently give myself.

My floor was full of elderly patients with cancer-related complications. There were three other women in my room who looked unwell. I was uncomfortable speaking to them and seeing the type of treatments they needed. The environment didnt promote positive thoughts, but I insisted on staying.

I sat in the emergency room for hours and was admitted because I was feeling sick. I didnt intend on leaving until I felt better, yet the constant suggestions made me feel like I was wasting National Health Service resources. I couldnt help but wonder if someone needed my bed more than me.

I was discharged Sept. 17, and I honestly regret not staying in the hospital. The pain is just as intense and Ive seriously considered going back.

This is just to encourage all you sickle cell warriors to stay put. If youre not feeling well enough to be discharged, you have every right to stay. You know your body best. If you feel awkward about advocating for yourself, speak to a friend or family member who can effectively relay the importance of staying in the hospital to the appropriate healthcare professionals.

***

Note: Sickle Cell Anemia News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Sickle Cell Anemia News or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to sickle cell anemia.

Read the original here:
Don't Be Shy About Asking to Remain in the Hospital - Sickle Cell Anemia News

Silencing of TAZ inhibits the motility of hepatocellular carcinoma cel | CMAR – Dove Medical Press

Wei Zhou,1,2,* Jiachun Weng,1,* Keyan Wu,1,2,* Xiao Xu,1,* Hui Wang,1,* Jing Zhang,3,* Chengxue Zhao,1 Jie Yang,1 Yu Zhang,1,4,5 Weigan Shen1,4,5

1Department of Cell Biology, School of Medicine of Yangzhou University, Yangzhou, Peoples Republic of China; 2Department of Internal Medicine, Affiliated Hospital of Yangzhou University, Yangzhou, Peoples Republic of China; 3Department of Internal Medicine, Northern Jiangsu Peoples Hospital Affiliated to Yangzhou University, Yangzhou, Peoples Republic of China; 4Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, Peoples Republic of China; 5Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou University, Yangzhou, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Yu Zhang; Weigan ShenDepartment of Cell Biology, School of Medicine of Yangzhou University, No. 136 Middle Jiangyang Street, Yangzhou 225009, Jiangsu, Peoples Republic of ChinaTel +86 05 148 797 8875Fax +86 05 148 734 1733Email yzzy10182001@aliyun.com; shenweigan@hotmail.com

Purpose: The aim of the present study was to investigate the effect of knockdown and knockout of the transcriptional co-activator with PDZ-binding motif (TAZ) on the migration, invasion and autophagy of the hepatocellular carcinoma (HCC) cell lines, as well as the functional connection between the autophagy and cell migratory processes induced by loss of TAZ in HCC cell lines.Methods: HCC cell lines SMMC-7721 and SK-HEP1 stably knockdown and knockout of TAZ were established by the lentiviral-mediated TAZ knockdown and knockout approaches. Reverse transcription-quantitative real-time polymerase chain reaction and Western blotting were performed to examine the expression of TAZ and indicated genes in downstream pathways in HCC cell lines. Transwell assay and autophagic flux assay were used to evaluate the effect of TAZ knockdown and knockout on the motility and the autophagy of HCC cell lines.Results: We initially found that TAZ exhibited highly abundant and was expressed predominantly in HCC cell lines with different spontaneous metastatic potential. Through performing loss-of-function assays, we demonstrated that both TAZ knockdown and knockout promoted HCC cell autophagy and reduced HCC cell migration, invasion and epithelial-to-mesenchymal transition. In addition, autophagy inhibition in TAZ knockdown and knockout SMMC-7721 and SK-HEP1 cells in the presence of 3-methyladenine or chloroquine partially abrogated the migratory and invasive ability induced by TAZ knockdown and knockout.Conclusion: Our findings indicated that loss of TAZ in HCC cells suppressed cell motility probably via altering the autophagy, suggesting that TAZ emerges as an important target in regulating cell motility and autophagy in HCC cells, and blocking TAZ may be a novel therapeutic strategy against HCC.

Keywords: TAZ, autophagy, migration, invasion, hepatocellular carcinoma

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Silencing of TAZ inhibits the motility of hepatocellular carcinoma cel | CMAR - Dove Medical Press

Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019 – GlobeNewswire

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced it will host a conference call and audio webcast on Monday, September 30 at 5:30 a.m. Pacific Time (8:30 a.m. ET) to review data from the Calithera clinical program presented at the European Society for Medical Oncology (ESMO) Congress 2019. Calithera management will review data from the ENTRATA study evaluating the glutaminase inhibitor telaglenastat and data presented on INCB001158, an oral arginase inhibitor.

Details of the ESMO 2019 oral late-breaking presentation for telaglenastat are as follows:

Date:Saturday, September 28, 2019, 8:30 a.m. CET, Barcelona AuditoriumSession Title: Proffered Paper 1-Genitourinary tumors, non-prostateAbstract Title: "ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat (CB-839) + everolimus vs. placebo + everolimus in patients with advanced/metastatic renal cell carcinoma (RCC)."R. Motzer, et al.Abstract:LBA54Presenter: Chung-Han Lee, M.D., PhD of the Memorial Sloan Kettering Cancer Center

Details of the oral presentation for INCB001158 are as follows:

Date:Sunday, September 29, 2019, 4:30 p.m. CET, Malaga AuditoriumSession Title: Proffered Paper Developmental therapeuticsAbstract Title: "Phase 1 study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab in patients with advanced/metastatic solid tumors."A. Naing, et al.Abstract:440O Presenter: Aung Naing, M.D., FACP, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Link: Abstract is available at https://www.esmo.org/Conferences/ESMO-Congress-2019

To participate in the Calithera ESMO 2019 Call, please dial (855) 783-2599 (domestic) or (631) 485-4877 (international) five minutes prior to the start of the call and provide the conference ID 1469186. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website at http://www.calithera.com. The webcast will be recorded and available for replay on Calitheras website for 30 days.

About Telaglenastat

Telaglenastat is an investigational first-in-class, novel glutaminase inhibitor specifically designed to block glutamine consumption in tumor cells. RCC tumors commonly exhibit metabolic alterations that increase their dependence on glutamine. In preclinical studies, telaglenastat produced synergistic antitumor effects when used in combination with standard-of-care RCC therapies. On June 17, 2019, Calithera announced that a randomized Phase 2 trial of telaglenastat plus everolimus versus everolimus plus placebo (ENTRATA) met its primary endpoint of improving progression free survival, demonstrating proof of concept for telaglenastat in patients with advanced RCC. The ongoing CANTATA trial is a global, randomized, double-blind trial designed to evaluate the safety and efficacy of telaglenastat plus cabozantinib versus placebo plus cabozantinib in patients with advanced or metastatic RCC.

About INCB001158 (CB-1158)

INCB001158 (CB-1158) is an investigational first-in-class, novel small molecule arginase inhibitor. Arginase is an enzyme that suppresses the immune-mediated destruction of tumors by depleting levels of a key amino acid, L-arginine, from the tumor microenvironment. A number of cell types in the tumor microenvironment, including myeloid-derived suppressor cells, macrophages, and neutrophils, can secrete arginase. L-arginine deprivation can act via nutrient sensor pathways to exert several suppressive effects on T-cell function, inhibiting proliferation, decreasing cytokine production, and diminishing expression of the T-cell receptor CD3 chain. Arginase activity may thus impair T-cell mediated anti-tumor responses. INCB001158 is being developed in a global collaboration with Incyte Corporation.

About Calithera

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit http://www.calithera.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calitheras product candidates, the overall advancement of Calitheras product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calitheras plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at http://www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

SOURCE:Calithera Biosciences, Incorporated

CONTACT:

Jennifer McNealeyir@Calithera.com650-870-1071

MEDIA CONTACT:Hannah Hurdlehannahhurdle@sambrown.com 805-338-4752

Read the rest here:
Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019 - GlobeNewswire

UCI School of Medicine researchers lead an international team for $4.3M NIH BRAIN Initiative award for new brain mapping tool – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Newswise Irvine, CA - September 26, 2019 Professors Xiangmin Xu and Rozanne Sandri-Goldin, in collaboration with Professors Bert Semler and Todd Holmes at the University of California, Irvine, School of Medicine, were awarded a three-year, $4.3 million Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative grant. Working together with a dream team of US and Chinese scientists, they will lead the development of a new brain mapping tool for neuroscience research.

The mapping tool is based on genetically engineered herpesviruses. Herpes simplex virus (HSV) type 1, strain 129 (H129) will be harnessed as an anterograde, monosynaptic viral tracer with high labeling efficacy and low toxicity for neural circuit analysis.

Current versions of genetically modified H129 herpesviruses are limited primarily by high virulence and toxicity, said Xu. We have a comprehensive plan to reduce the toxicity and also to enhance signal outputs and generate variants carrying different functional payloads. Ultimately, we will be able to create a new set of safe, effective and validated anterograde-directed viral vectors.

Expected to have broad impact, the new tool will be made available through the UCI Center for Virus Research where it can be disseminated to the entire neuroscience community.

"The development of trans-synaptic viral tracers is an important component of the BRAIN Initiative, said Xu.At present, the lack of viral-based anterograde, monosynaptic tracing tools with high signal strength and low toxicity is a critical gap in neuroscience, preventing researchers from gaining a full understanding of how the brain works.

The team is excited about the prospect that new recombinant H129 viral vectors will lead to transformative tools for neuroscience research, and in the more distant future, clinical applications for human diseases such as Alzheimer's disease, Parkinson's disease and epilepsy. Xu and Sandri-Goldin have assembled a collaborative, interdisciplinary team composed of virologists and systems neuroscientists to develop the new neural analysis tool. Other principal investigators include Professor Gregory D. Horwitz from the University of Washington and Professor Min-Hua Luo from the Wuhan Institute of Virology, Chinese Academy of Sciences.

Their research proposal, "Genetically engineered anterograde monosynaptic viral tracers for multi-species neural circuit analysis, was submitted in response to a special RFA as part of the BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain.

About the NIH BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a revolutionary new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space. Long desired by researchers seeking new ways to treat, cure, and even prevent brain disorders, this picture will fill major gaps in our current knowledge and provide unprecedented opportunities for exploring exactly how the brain enables the human body to record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought. For more information, visit: https://www.braininitiative.nih.gov/

About the UCI School of Medicine

Each year, the UCI School of Medicine educates more than 400 medical students, as well as 200 doctoral and masters students. More than 600 residents and fellows are trained at UC Irvine Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

Originally posted here:
UCI School of Medicine researchers lead an international team for $4.3M NIH BRAIN Initiative award for new brain mapping tool - Newswise